Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26308881 | 0.85 | HCAR2 (0.62) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL16891501 | 0.81 | POLB (0.58) | HCAR2CYP2C19SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL17819609 | 0.81 | HCAR2 (0.62) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL11243516 | 0.80 | HCAR2 (0.51) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL1203317 | 0.79 | HCAR2 (0.60) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL5570090 | 0.78 | HSD17B3 (0.52) | HSD17B3HPGDSMN1; SMN2L3MBTL1RAB9A | |
| Bromide SCHEMBL17504050 | 0.78 | HCAR2 (0.58) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL17819556 | 0.77 | MKNK1 (0.44) | HSD17B3CYP2C19HPGDALDH1A1HSD17B10 | |
| SCHEMBL21240973 | 0.76 | HCAR2 (0.56) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL29939950 | 0.76 | ATM (0.56) | HCAR2ATMSMYD3CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2277865-B1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2014-11-12 | — | — | EP | disclosed |
| US-20110269760-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-11-03 | — | — | US | disclosed |
| US-20110269760-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-11-03 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| EP-1689715-B1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2011-02-09 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | HCAR2 4465/4885ATM 748/4885HSD17B3 1908/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | HCAR2 4522/4885ATM 735/4885HSD17B3 2055/4885 |
| US-20110269760-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | HCAR2 4465/4885ATM 748/4885HSD17B3 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.